S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
S&P 500   2,466.65 (-2.38%)
DOW   20,914.98 (-2.33%)
QQQ   181.77 (-2.28%)
AAPL   240.07 (-1.98%)
FB   151.03 (-4.53%)
GOOGL   1,081.49 (-3.68%)
AMZN   1,891.91 (-1.50%)
CGC   13.44 (-2.68%)
NVDA   240.03 (-6.04%)
BABA   185.65 (-1.72%)
MU   40.82 (-0.66%)
GE   6.61 (-4.20%)
TSLA   474.30 (+4.36%)
T   27.55 (-4.21%)
ACB   0.81 (-3.58%)
F   4.20 (-3.67%)
NFLX   358.13 (-3.23%)
BAC   19.77 (-3.89%)
GILD   78.08 (+1.43%)
DIS   93.73 (-3.34%)
Log in

NYSE:HEPA - ContraVir Pharmaceuticals Stock Price, Forecast & News

$1.53
-0.10 (-6.13 %)
(As of 04/3/2020 02:21 PM ET)
Today's Range
$1.53
Now: $1.53
$1.62
50-Day Range
$1.15
MA: $3.03
$5.09
52-Week Range
$1.00
Now: $1.53
$21.00
Volume4,925 shs
Average Volume689,128 shs
Market Capitalization$5.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. Hepion Pharmaceuticals, Inc. has a research partnership with Applied Pharmaceutical Innovation. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone732-902-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Market Cap$5.28 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive HEPA News and Ratings via Email

Sign-up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.


ContraVir Pharmaceuticals (NYSE:HEPA) Frequently Asked Questions

How has ContraVir Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ContraVir Pharmaceuticals' stock was trading at $2.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HEPA shares have decreased by 26.8% and is now trading at $1.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ContraVir Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ContraVir Pharmaceuticals.

When is ContraVir Pharmaceuticals' next earnings date?

ContraVir Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for ContraVir Pharmaceuticals.

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

News coverage about HEPA stock has trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ContraVir Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutContraVir Pharmaceuticals.

Who are some of ContraVir Pharmaceuticals' key competitors?

What other stocks do shareholders of ContraVir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Aethlon Medical (AEMD), Agile Therapeutics (AGRX), Amarin (AMRN), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Opko Health (OPK), Cassava Sciences (SAVA) and VBI Vaccines (VBIV).

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the following people:
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., Pres, CEO & Director (Age 61)
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant (Age 71)
  • Mr. John T. Cavan, Chief Financial Officer (Age 61)
  • Dr. Daren Ure Ph.D., Chief Scientific Officer
  • Sharen Pyatetskaya, Director of Investor Relations

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "HEPA."

How do I buy shares of ContraVir Pharmaceuticals?

Shares of HEPA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of HEPA stock can currently be purchased for approximately $1.53.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $5.28 million. ContraVir Pharmaceuticals employs 14 workers across the globe. View additional information about ContraVir Pharmaceuticals.

What is ContraVir Pharmaceuticals' official website?

The official website for ContraVir Pharmaceuticals is http://www.hepionpharma.com/.

How can I contact ContraVir Pharmaceuticals?

The company can be reached via phone at 732-902-4000.


MarketBeat Community Rating for ContraVir Pharmaceuticals (NYSE HEPA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  18
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe HEPA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEPA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: Strike Price

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel